

NCI Alliance for  
**Nanotechnology**  
in Cancer

# NCI Alliance for Nanotechnology in Cancer: Research Advances and Development of Clinical Applications

**Anna D. Barker, Ph.D.**

Deputy Director, National Cancer Institute

National Cancer Advisory Board Meeting

**June 14, 2006**


# The Potential of Nanotechnology

NCI Alliance for  
**Nanotechnology**  
in Cancer

**Nanotechnology** has the potential to be the key enabler for the transition of molecular-based science into the clinic, facilitating major advances in the early detection, diagnosis, and treatment of cancer.

# Detection, Treatment, Prevention: Nanotech from Bench to Bedside

NCI Alliance for  
**Nanotechnology**  
in Cancer



# NCI Strategic Approach to Nanotech

NCI Alliance for  
**Nanotechnology**  
in Cancer

- **Early investments**
  - Novel technologies through the Unconventional Innovations Program since 1998
- **Counsel from the community**
  - Input from the scientific, cancer research and advocacy communities
- **Planning a comprehensive effort**
  - Cancer Nanotechnology Plan to drive systems-level change and catalyze product development
- **Launch of the Alliance**
  - NCI Alliance for Nanotechnology in Cancer in 2004
- **Milestone-driven execution**
  - Defined programs; collaborators; milestones; reporting processes



# NCI Alliance for Nanotechnology in Cancer

NCI Alliance for  
**Nanotechnology**  
in Cancer

## **Goals:**

- Research tools to identify new biological targets
- Agents to monitor predictive molecular changes and prevent precancerous cells from becoming malignant
- Imaging agents and diagnostics to detect cancer in earliest, most easily treatable, pre-symptomatic stage
- Multifunctional targeted devices to deliver multiple therapeutic agents directly to cancer cells
- Systems to provide real-time assessments of therapeutic and surgical efficacy
- Novel methods to manage symptoms that reduce quality of life


# NCI Nanotech Alliance Programs

NCI Alliance for  
**Nanotechnology**  
in Cancer

- Centers of Cancer Nanotechnology Excellence
- Nanotechnology Platforms for Cancer Research
- Multidisciplinary Research Teams
  - Training
  - Interagency Collaborations
- Nanotechnology Characterization Laboratory

# NCI Nanotech Alliance Program Awards

NCI Alliance for  
**Nanotechnology**



# NCI-NSF Nanobiotechnology Collaboration: Training the Next Generation

NCI Alliance for  
**Nanotechnology**  
in Cancer





# Interagency Collaborations

NCI Alliance for  
**Nanotechnology**  
in Cancer

- **Standards/Precision Measurement Capabilities**



- **Training**
- **Dissemination of Results**



- **Public Interface**
- **Interpret Data on Environment, Health and Safety**

- **Shared Data and Platforms**

# Nanotechnology Characterization Laboratory (NCL)

NCI Alliance for  
**Nanotechnology**  
in Cancer

- NCL Role:
  - Interface with CCNEs, individual investigators, NIST and FDA to develop standards and characterization data for nanoscale materials
  - Perform preclinical toxicology, pharmacology, and efficacy testing of nanoscale devices
  - Formulate and validate protocols for physical, *in vitro*, and ADME/tox characterization of nanoparticles

NATIONAL  
CANCER  
INSTITUTE

FDA



# Novel Attributes of the NCI Nanotech Alliance

Steady interaction among Alliance participants and the community through:

- Governance Committee
- Continual evaluation of project programs through performance milestones
- Teleconferences
- Technology Transfer, Intellectual Property, and Communications Working Groups
- Website with “Knowledge Environment” and secure Intranet for Alliance members
- Advocacy involvement on an ongoing basis

# NCI Nanotech Alliance: The Challenge and Deliverables

- Produce tangible solutions which are clinically applicable, in a short period of time
- Medical community expects significant advances:
  - Where solutions are currently non-existent
  - Where replacement technologies are superior to existing methods
- Identify “early successes”
- Program as viable addition to existing NCI funding portfolio:
  - Well interconnected
  - Truly produces a paradigm change